Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Ulrich Jaeger, MD, Alexander Egle, MD, Ingrid Simonitsch-Klupp, MD, Sonja Heibl, MD, Peter Neumeister, MD, Ella Willenbacher, MD, Florian Erlsbacher, Julian Larcher-Senn, Michael A. Fridrik, MD, Richard Greil, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-136953

Published: 2020

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Blood (2018) 132 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2018-99-110555

Published: 2018

Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Blood (2017) 130 (Supplement 1): 2769.

https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769

Published: 2017

Journal Articles

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Thomas Reiter, MD, Marlies Antlanger, Alexandra Böhm, Wolfgang Lamm, Max Gornicec, Ella Willenbacher, MD, David Nachbauer, Werner Rabitsch, Daniel Lechner, MD, Hildegard Greinix, Felix Keil, MD, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5424.

https://doi.org/10.1182/blood.V130.Suppl_1.5424.5424

Published: 2017

Journal Articles

Bone Marrow CD4+ and CD8+ Lymphocyte Infiltration Patterns Define Overall- and Progression Free Survival in Multiple Myeloma and May Predict IMiD Response: an Analysis from the Austrian Myeloma Registry

Ella Willenbacher, MD, Andrea Brunner-Veber, MD PhD, Roman Weger, Mag., Wolfgang Willenbacher, MD

Blood (2016) 128 (22): 5659.

https://doi.org/10.1182/blood.V128.22.5659.5659

Published: 2016

Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Blood (2015) 126 (23): 1603.

https://doi.org/10.1182/blood.V126.23.1603.1603

Published: 2015

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Ella Willenbacher, MD, Wolfgang Willenbacher, MD, Gunther Gastl, Prof., Dr., Irmgard Verdorfer, MDPhD, Brigitte Kircher, PhD

Blood (2014) 124 (21): 5732.

https://doi.org/10.1182/blood.V124.21.5732.5732

Published: 2014

Journal Articles

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

Ella Willenbacher, MD, Alfons Kreczy, MD, Christian Uprimny, MD, Brigitte Bucher, MD, Guenther A. Gastl, MD, Wolfgang Willenbacher, MD

Blood (2013) 122 (21): 5124.

https://doi.org/10.1182/blood.V122.21.5124.5124

Published: 2013

Journal Articles

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Ursula Rochau, MSc, Wolfgang Willenbacher, MD, Ella Willenbacher, MD, Beate Jahn, MSc, Vjollca Querimi, MD, Christina Kurzthaler, MSc, Martina Kluibenschaedl, MSc, Annette Conrads-Frank, MSc, Guenther A. Gastl, MD, Uwe Siebert, MD PhD MSc

Blood (2013) 122 (21): 2991.

https://doi.org/10.1182/blood.V122.21.2991.2991

Published: 2013

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2012) 120 (21): 175.

https://doi.org/10.1182/blood.V120.21.175.175

Published: 2012

Journal Articles

Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study

Heinz Gisslinger, MD, Robert Kralovics, PhD, Renate Schoder, Bettina Gisslinger, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Dominik Wolf, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Franz-Josef Tarmann, MSc, Christoph Wachter, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2011) 118 (21): 1747.

https://doi.org/10.1182/blood.V118.21.1747.1747

Published: 2011

NARROW

Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Bone Marrow CD4+ and CD8+ Lymphocyte Infiltration Patterns Define Overall- and Progression Free Survival in Multiple Myeloma and May Predict IMiD Response: an Analysis from the Austrian Myeloma Registry

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) Combination

Fast Achievement Of a First Metabolic Complete Remission In a Lung Transtplanted Patient With Multiple Comorbidities and a CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy

Methodological Characteristics Of Decision-Analytic Modeling Studies For The Treatment Of Multiple Myeloma

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only